Cargando…

Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group

Early-stage breast cancer (BC) is a curable disease with many patients dying of causes other than BC. The influence of non-BC death and other competing risks on the interpretation of Kaplan-Meier (KM)-based analyses for BC-specific outcomes are unknown. We searched the Oxford University website to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saleh, Ramy R., Nadler, Michelle B., Desnoyers, Alexandra, Rodin, Danielle L., Abdel-Qadir, Husam, Amir, Eitan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058037/ https://www.ncbi.nlm.nih.gov/pubmed/32139756 http://dx.doi.org/10.1038/s41598-020-61093-0

Ejemplares similares

Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation
por: Abdel-Qadir, Husam, et al.
Publicado: (2019)

A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time
por: Wilson, Brooke E., et al.
Publicado: (2022)

Importance of Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation
por: Abdel-Qadir, Husam, et al.
Publicado: (2018)

Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer
por: Suntheralingam, Sivisan, et al.
Publicado: (2022)

The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study
por: Abdel-Qadir, Husam, et al.
Publicado: (2019)

Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study
por: Abdel‐Qadir, Husam, et al.
Publicado: (2021)

Perceived guideline clarity impacts guideline-concordant care for breast cancer screening in women age 40–49
por: Nadler, Michelle B., et al.
Publicado: (2023)

Competing risks analyses for recurrence from primary breast cancer
por: Chapman, J W, et al.
Publicado: (1999)

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer
por: Desnoyers, A., et al.
Publicado: (2022)

Determinants of guideline-concordant breast cancer screening by family physicians for women aged 40–49 years: a qualitative analysis
por: Nadler, Michelle B., et al.
Publicado: (2022)

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
por: Wilson, Brooke E., et al.
Publicado: (2021)

Confessions of a chagrined trialist
por: Goodman, Steven
Publicado: (2011)

Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists
por: Trivedi, Palak J., et al.
Publicado: (2015)

Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study
por: Abdel-Qadir, Husam, et al.
Publicado: (2021)

Conflicts of Interest, Baselga, and Clinical Trialists
por: Sartor, Oliver
Publicado: (2018)

Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST)
por: Gasparri, Maria Luisa, et al.
Publicado: (2020)

Competing risks to breast cancer mortality in Catalonia
por: Vilaprinyo, Ester, et al.
Publicado: (2008)

Individual patient data meta-analysis of acupuncture for chronic pain: protocol of the Acupuncture Trialists' Collaboration
por: Vickers, Andrew J, et al.
Publicado: (2010)

Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers
por: Al-Showbaki, Laith, et al.
Publicado: (2021)

Metformin to Prevent Anthracycline Cardiotoxicity?: That Would Be Sweet!
por: El-Rayes, Malak, et al.
Publicado: (2023)

Competing Risk Analyses of Medullary Carcinoma of Breast in Comparison to Infiltrating Ductal Carcinoma
por: Dai, Dongjun, et al.
Publicado: (2020)

Hormone Therapy, Breast Cancer Risk and the Collaborative Group on Hormonal Factors in Breast Cancer Article
por: Pompei, Luciano de Melo, et al.
Publicado: (2020)

The natural history of conducting and reporting clinical trials: interviews with trialists
por: Smyth, Rebecca MD, et al.
Publicado: (2015)

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.
por: Aabo, K., et al.
Publicado: (1998)

Competing risks determining event-free survival in early breast cancer.
por: Arriagada, R., et al.
Publicado: (1992)

Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy
por: Bonsignore, Alis, et al.
Publicado: (2021)

Self-Reported Physical Activity, QoL, Cardiac Function, and Cardiorespiratory Fitness in Women With HER2+ Breast Cancer
por: Peck, Serena S., et al.
Publicado: (2022)

Modified Routine Cardiac Imaging Surveillance of Adult Cancer Patients and Survivors During the COVID-19 Pandemic
por: Calvillo-Argüelles, Oscar, et al.
Publicado: (2020)

Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists
por: Smyth, R M D, et al.
Publicado: (2011)

The trialists’ perspectives on the participant retention in mental health randomised controlled trials
por: Szymczynska, Paulina, et al.
Publicado: (2015)

Trialists perspectives on sustaining, spreading, and scaling-up of quality improvement interventions
por: Laur, Celia, et al.
Publicado: (2021)

Competing risks analyses: objectives and approaches
por: Wolbers, Marcel, et al.
Publicado: (2014)

Adjusting for BMI in analyses of volumetric mammographic density and breast cancer risk
por: Hudson, Sue, et al.
Publicado: (2018)

Defining a Clinically Meaningful Benefit in Cancer Clinical Trials: From the Perspectives of the Clinical Trialist, Patient, and Society
por: Moon, Dominic H, et al.
Publicado: (2018)

Prediction the survival of patients with breast cancer using random survival forests for competing risks
por: NAJAFI-VOSOUGH, ROYA, et al.
Publicado: (2022)

Obesity/Weight Gain and Breast Cancer Risk: Findings From the Japan Collaborative Cohort Study for the Evaluation of Cancer Risk
Publicado: (2013)

Do trialists endorse clinical trial registration? Survey of a Pubmed sample
por: Reveiz, Ludovic, et al.
Publicado: (2007)

Sharing of clinical trial data among trialists: a cross sectional survey
por: Rathi, Vinay, et al.
Publicado: (2012)

Combination of Osimertinib with Concurrent Chemotherapy and Hormonal Therapy for Synchronous NSCLC, Hormone Receptor-Positive Breast Cancer, and Triple-Negative Breast Cancer: Case Report
por: Park, Changsu L., et al.
Publicado: (2023)

Obstructive sleep apnea and its management in patients with atrial fibrillation: An International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT) global survey of practicing cardiologists
por: Faulx, Michael D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d48qfabvj3dbngdmtd13ag7kn0